Yangling Jinhai Biotechnology Co., Ltd. announced that it expects to receive CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership
March 14, 2021
Share
Yangling Jinhai Biotechnology Co., Ltd. announced that it will raise CNY 80,000,000 in an equity round of funding on March 15, 2021. The transaction will involve participation from new investor Shanghai Runling Investment Partnership for CNY 60,000,000 and returning investor Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) for CNY 25,000,000. Post the closing, the stake of Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) will increase from 55% to 76.07% and Shanghai Runling Investment Partnership will hold 21.43% stake in the company. The registered capital of the company is CNY 100,000,000. Post the completion, the registered capital of the company will become CNY 200,000,000, and CNY 40,000,000 will be included in the capital reserve. The transaction has been approved at the 23rd meeting of the third board of directors of Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.
Yangling Jinhai Biotechnology Co., Ltd. announced that it expects to receive CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership